MannKind in Jeopardy

MannKind Corp. (MNKD) recently suffered a major setback with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for its new drug application (NDA) for type I and type II diabetes treatment Afrezza. MannKind’s share price plummeted 44% in after hours trading, following the announcement of the news. We note that [...]